Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5

Conditions

Leukemia, Myeloid, Acute 59Myelodysplastic Syndromes 14Leukemia 11Recurrence 5Leukemia, Promyelocytic, Acute 5Congenital Abnormalities 5Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Erythroblastic, Acute 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Megakaryoblastic, Acute 3Neoplasm, Residual 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Sarcoma, Myeloid 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Disease Progression 1Disease 1Blast Crisis 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Recurrence × Gemtuzumab × Clear all
NCT04070768 2025-05-04

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Big Ten Cancer Research Consortium

Phase 1 Completed
18 enrolled 15 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04050280 2025-05-01

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

University of Maryland, Baltimore

Phase 2 Recruiting
39 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Brown University

Phase 2 Active not recruiting
11 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Disease Progression

NCT04173585 2023-03-27

TEAM

University Hospital Heidelberg

Phase 2 Completed
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00660036 2016-01-15

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

University of Pittsburgh

Phase 1 Terminated
5 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡